Study of Extracellular Vesicles (EV) in Patients Undergoing CAR-T Cell Therapies

Recruiting now

Conditions studied: CAR-T Cell Therapy, Extracellular Vesicles

In brief

Patients with refractory/relapse hematologic oncology disease may benefit from innovative therapy such as Car-T cells. Factors strongly predictive of outcome and response are unknown. Extracellular vesicles are recognized as a mode of intercellular communication and are reminiscent of the cell of origin. They are currently candidates to be biomarkers for this biomarker of phenomena occurring in tissues. The working hypothesis is that they may be predictive of outcome and toxicity, as some preliminary data have suggested. Therefore, the aim of the study concerns I dentification of potential CAR-EV biomarkers associated with neurological toxicity after infusion of CAR-T cells.

Key facts

Study ID

NCT06554951

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

100

Starts

2024-08-31

Expected to finish

2026-08-31

Last updated by the study team

2024-12-27

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients affeccted by any hematological malignancies (r/r B cell lymphoma, B cell acute leukemia and multiple myeloma) undergoing (or whit indication to) CAR-T cell infusion with a CAR-T cell product;
• age: 18 years or greater;
• obtained written consent to the study participation.

You may not qualify if…

• none

Where it is running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Bologna, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.